Articles tagged "Antibodies"

2016 American Transplant Congress
Natural Killer CD16/FcR Profiles May Associate with Enhanced Humoral Responsiveness in Heart Transplant Recipients with Cardiac Allograft Vasculopathy.
P. Paul,^1,2 C. Picard,^3,4 E. Sampol,⁵ L. Lyonnet,¹ J. Di Cristofaro,^3,4 G. Lano,^6, B. Dussol,^6, F. Collart,⁷ F. Sabatier,^1,2 F. Dignat George,^1,2 A. Mouly Bandini.⁷
¹Hematology, Assistance Publique-Hopitaux Marseille (AP-HM), Marseille, France; ²UMR-1076, Aix Marseille Université (AMU), INSERM, Marseille, France; ³Établissement Français du Sang, Marseille, France; ⁴UMR7268, AMU, CNRS, Marseille, France; ⁵Pharmacokinetics, AP-HM, Marseille, France; ⁶Center for Clinical Investigation, AP-HM, Marseille, France; ⁷Cardiac Surgery, AP-HM, Marseille, France.
Natural Killer cells (NK) are immune effectors of antibody-dependent cellular cytotoxicity (ADCC). Their role in mediating adverse effects of Donor-specific anti-HLA antibodies (DSA) towards cardiac…
2015 American Transplant Congress
B Cell Depletion With an Anti-CD20 Antibody Enhances Alloreactive Memory T Cell Response After Transplantation
J. Marino, P. Crosby Bertorini, J. Paster, A. Trowell, K. Briggs, L. Maxwell, G. Benichou.
Surgery Department, Center for Transplantation Sciences, Massachusetts General Hospital / Harvard Medical School, Boston, MA.
Pre-transplant B cell depletion in NHP with Rituximab (IgG1 anti-CD20 mAb) combined with cyclosporin A has been shown to promote the survival of islets allografts.…
2015 American Transplant Congress
Immune Response to Kidney and Pancreas Self-Antigens Are Associated With Antibody Mediated Rejection in Simultaneous Kidney Pancreas Transplants
M. Gunasekaran,¹ A. Siddiq,² S. Shenoy,¹ J. Wellen,¹ T. Mohanakumar.¹
¹Surgery, Washington Univ Sch of Med, St. Louis, MO; ²Medicine, Washington Univ Sch of Med, St. Louis, MO.
Background: Simultaneous kidney-pancreas transplantation (SKP Tx) is performed as treatment option for type-1 diabetes with end stage kidney diseases. Though allograft survival was improved with…
2015 American Transplant Congress
Immune-Mediated Injury in Kidney Transplant Recipients Treated With Alemtuzumab Induction and a Steroid Avoidance Protocol
R. Sapir-Pichhadze, T. Mahbub, C. Saw, D. Baran.
McGill University Health Centre, Montreal, Canada.
Study purpose: We evaluated short-term clinical and immunological outcomes of kidney transplant recipients who received alemtuzumab induction and a steroid-avoidance protocol.Methods: This is a retrospective…
2015 American Transplant Congress
Efficacy of Rituximab Sparing Protocol for ABO Incompatible Renal Transplant in Patients With Low Titers
S. Narumi,¹ Y. Watarai,¹ N. Goto,¹ T. Hiramitsu,¹ T. Yamamoto,¹ M. Tsujita,¹ M. Okada,¹ K. Futamura,¹ A. Takeda,² T. Kobayashi.³
¹Transplant Surgery, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ²Nephrology, Nagoya Daini Red Cross Hospital, Nagoya, Aichi, Japan; ³Applied Immunology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
[Introduction]Acute antibody mediated rejection (AMR) has been a major problem in ABO-incompatible kidney transplantation (ABOi-KTx), and currently mycophenolate mofetil and rituximab have been used to…
2015 American Transplant Congress
Inhibition of Endogenous Memory CD8 T Cell Infiltration Into Cardiac Allografts Subjected to Prolonged Cold Ischemic Storage Is Required to Promote Long-Term Graft Survival
N. Kohei,¹ H. Tsuda,^1,3 T. Tanaka,^1,4 S. Iida,² T. Abe,³ C. Su,¹ D. Kish,¹ K. Tanabe,² A. Valujskikh,¹ R. Fairchild.¹
¹Immunology, Cleveland Clinic, Cleveland, OH; ²Urology Kidney Center, Tokyo Women's Medical University, Tokyo, Japan; ³Urology, Osaka University, Osaka, Japan; ⁴Urology, Sapporo Medical University, Sapporo, Japan.
Endogenous memory CD8 T cells infiltrate MHC-mismatched cardiac allografts and produce IFN-γ in response to donor class І MHC within 24 hrs after graft reperfusion…
2015 American Transplant Congress
Are AT1R Antibodies as Dangerous as HLA-DSAs in Renal Allografts?
E. Cuevas, J. Arreola-Guerra, E. Hernandez-Mendez, I. Salcedo, M. Vilatoba, A. Contreras, A. Sanchez-Cedillo, J. Ramirez, D. de Rungs, J. Granados, L. Morales-Buenrostro, J. Alberu.
1Transplantation, 1aNephrology-Mineral Metabolism, Inst Nal de Ciencias Medicas y Nutricion SZ, Mexico City, Distrito Federal, Mexico.
Angiotensin II type 1 receptor antibodies (AT1Rab) have been associated with a significantly lower graft survival and a higher risk of acute rejection after kidney…
2015 American Transplant Congress
DSA Monitoring in Kidney Transplant Recipients
F. Pean,¹ M. Cooper,¹ J. Verbesey,¹ A. Gilbert,¹ B. Javaid,¹ R. Mohammed,¹ O. Timofeeva,² J. Moore,¹ K. Cruz,¹ R. Ghasemian,¹ T. Fishbein,¹ M. Grafals.¹
¹Medstar Georgetown Transplant Institute, Georgetown University, Washington, DC; ²Clinical Laboratory and Histocompatibility, Georgetown University, Washington, DC.
Introduction: The development of DSA monitoring is a new technique to detect antibodies in kidney transplant recipients. Data has shown that development of DSA post…
2015 American Transplant Congress
Mesenchymal Stem Cells (MSCs) Transfusion for Desensitization of Positive Lymphocyte Cross Match (LCM) or Panel Reactive Antibodies (PRA) Before Kidney Transplantation – Outcome of 16 Cases
G. Saadi,¹ K. Eweda,² M. Hassaballa,¹ F. Fadel,³ E. Aziz,² M. Roshdi,¹ M. El Ansary,⁴ I. Aziz,⁴ W. Ismail,⁵ A. Atef,¹ S. Hamid.⁴
¹Internal Medicine and Nephrology, Cairo University, Cairo, Egypt; ²Nephrology, Army Hospital, Cairo, Egypt; ³Pediatric Nephrology, Cairo University, Cairo, Egypt; ⁴Clinical Pathology, Cairo University, Cairo, Egypt; ⁵Pathology, Beni Sweif University, Beni Sweif City, Egypt.
Immunomodulatory function of MSCs may correct positive PRA or LCM in highly-sensitized patients. We evaluate donor specific or 3rd party MSCs transfusion in 16 patients…
2015 American Transplant Congress
Evaluation of Donor-Specific Antibodies Through 7 Years With Belatacept in BENEFIT and BENEFIT-EXT
R. Bray,¹ H. Gebel,¹ R. Townsend,² U. Meier-Kriesche,² C. Larsen.¹
¹Emory University, Atlanta; ²Bristol-Myers Squibb, Lawrenceville.
Purpose: The development of donor-specific antibody (DSA) is linked to an increased risk of antibody-mediated rejection and graft failure. The 3 year intent-to-treat results from…